biostudies-literatureMeessen JMTAitalian ministry of healthFondazione Umberto Veronesi1452-1466https://www.ebi.ac.uk/biostudies/studies/S-EPMC7373944biostudies-literatureUnknown7(4)<h4>Aims</h4>A multicentre trial, ICOS-ONE, showed increases above the upper limit of normality of cardiac troponin (cTn) in 27% of patients within 12 months after the end of cancer chemotherapy (CT) with anthracyclines, whether cardiac protection with enalapril was started at study entry in all (prevention arm) or only upon first occurrence on supra-normal cTn (troponin-triggered arm). The aims of the present post hoc analysis were (i) to assess whether anthracycline-based treatment could induce cardiotoxicity over 36 month follow-up and (ii) to describe the time course of three cardiovascular biomarkers (i.e. troponin I cTnI-Ultra, B-type natriuretic peptide BNP, and pentraxin 3 PTX3) and of left ventricular (LV) function up to 36 months.<h4>Methods and results</h4>Eligible patients wereESC heart failureCirculating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial.PMC7373944PE-2013-02356818Ricerca Finalizzata: RF-2009-1505746);year 2012RF-2009-1505746Pastori PNassiacos DCardinale DFranzosi MGCipolla CMSandri MTGori SMilandri CNicolis EBStaszewsky LCiceri FCortesi PCurigliano GMasson SBottazzi BLeone RCivelli MFalci CCucchi GMeessen JMTAMangiavacchi MFarolfi ABianchi ANovelli DMonopoli ACondorelli GColombo ABalconi GVerusio CMalossi ABarbieri ELatini RGhisoni FBregni MGarlanda CICOS-ONE Study InvestigatorsSalvatici MMenatti EMantovani AfalseCirculating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial.<h4>Aims</h4>A multicentre trial, ICOS-ONE, showed increases above the upper limit of normality of cardiac troponin (cTn) in 27% of patients within 12 months after the end of cancer chemotherapy (CT) with anthracyclines, whether cardiac protection with enalapril was started at study entry in all (prevention arm) or only upon first occurrence on supra-normal cTn (troponin-triggered arm). The aims of the present post hoc analysis were (i) to assess whether anthracycline-based treatment could induce cardiotoxicity over 36 month follow-up and (ii) to describe the time course of three cardiovascular biomarkers (i.e. troponin I cTnI-Ultra, B-type natriuretic peptide BNP, and pentraxin 3 PTX3) and of left ventricular (LV) function up to 36 months.<h4>Methods and results</h4>Eligible patients were2020-01-01T00:00:00Z2020 Aug2025-06-01T02:54:11.994Z2025-06-01T02:54:11.994ZS-EPMC73739443235891710.1002/ehf2.12695